1993-1999

- 1993: Company founded
- 1994: U.S. subsidiary established
- 1996: Launch of the first Spectral imaging product (SKY) and SKY Paints Probes
- 1997: Patent granted for cancer cell classification by spectral imaging, using the differential staining properties of standard stains
- 1998: Established European office and presence
- 1998: Patent granted for cancer cell classification by spectral imaging
- 1998: Patent granted for method of and composite for fluorescent in-situ hybridization
- 1998: Patent granted for optical device with entrance and exit paths that are stationary under device rotation
- 1999: Launch of FISH analysis software

2001-2007

- 2001: **FDA cleared for BandView product**
- 2001: Patent granted for method and article for improving optical detection and sensitivity
- 2001: Patent granted: Method and article for improving optical detection and sensitivity
- 2003: Launch of Cytogenetic Portfolio
- 2004: Selected as LabCorp's exclusive provider of cytogenetic imaging across North America
- 2005: Launch of cytogenetics karyotyping and automated scanning system
- 2005: **FDA cleared for FISHView product**
- 2006: Launch of automation scanning system for FISH & Karyotyping
- 2007: Patent granted for methods and systems for analyzing biological samples
- 2007: **FDA Cleared for SpotScan application for CEP XY**

2008-Present

- 2008: Selected as Genzyme Genetics' exclusive provider of Cytogenetic imaging across North America
- 2010: **FDA cleared for SpotScan application for HER2/neu**
- 2011: Launch of GenASIs platform including high throughput tray loader
- 2011: **FDA cleared for SpotScan application for UroVysion**
- 2012: Launch of Bright Field pathology systems for IHC analysis
- 2013: **FDA cleared for SpotScan application for ALK**
- 2015: **FDA cleared for HiPath system for IHC Family HER2, ER, PR, and Ki67**
- 2015: Patent granted for issuance for methods and system for spectral imaging, US, EU and Canada
- 2017: Launch of PathFusion & HiPATH Pro- ASI's full pathology imaging suite for H&E, IHC & FISH including tissue matching and WSI
- 2019: **FDA clearance for PD-L1 (in process)**